Previous studies have reported prognostic factors for hepatocellular carcinoma (HCC) patients receiving lenvatinib; however, no studies have evaluated the effects of both handgrip strength and skeletal muscle mass on the clinical outcomes. Therefore, this retrospective study investigated the individual effect of handgrip strength, skeletal muscle mass, and sarcopenia on clinical outcomes of 53 HCC patients treated with lenvatinib. Before receiving lenvatinib, handgrip strength and skeletal muscle index (SMI) were measured. Low handgrip strength and muscle depletion were defined as <26 and <18 kg and SMI <42 and SMI <38 cm²/m² in men and women, respectively. Sarcopenia was defined as having low handgrip strength and muscle depletion. Multivariate analysis identified modified albumin–bilirubin grade 1–2a (p = 0.010), Barcelona Clinic Liver Cancer stage A–B (p = 0.011), and absence of low handgrip strength (p = 0.015) as favorable prognostic factors for survival. Furthermore, sarcopenia was an independent significant prognostic factor for survival. Time to treatment failure was associated with handgrip strength and sarcopenia. Our findings suggest that handgrip strength may be a useful marker of clinical outcomes in HCC patients treated with lenvatinib.

中文翻译：

---

握力对雷伐替尼治疗肝细胞癌患者临床疗效的影响

先前的研究报道了接受来伐替尼治疗的肝细胞癌（HCC）患者的预后因素。然而，尚无研究评估握力和骨骼肌质量对临床结局的影响。因此，这项回顾性研究调查了握力，骨骼肌质量和肌肉减少症对53例接受lenvatinib治疗的HCC患者临床疗效的个体影响。在接受lenvatinib之前，先测量握力和骨骼肌指数（SMI）。低握力和肌肉消耗定义为<26和<18 kg，SMI <42和SMI <38 cm ² / m ²分别在男人和女人。肌肉减少症被定义为具有低握力和肌肉消耗。多元分析确定改良的白蛋白-胆红素等级为1-2a（p = 0.010），巴塞罗那临床肝癌AB期（p = 0.011）和缺乏低握力（p = 0.015）是存活的有利预后因素。此外，肌肉减少症是生存的独立重要预后因素。治疗失败的时间与握力和肌肉减少有关。我们的研究结果表明，握力强度可能是接受lenvatinib治疗的HCC患者临床结局的有用标志。